Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 12/20 | 0.67 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30819467 | 1.00 | PDE10A (0.67) | PDE10ALGALS3PDE4D | |
| SCHEMBL13772728 | 0.92 | PDE10A (0.68) | PDE10ALGALS3PDE4D | |
| SCHEMBL17088204 | 0.89 | PDE10A (0.67) | PDE10ALGALS3PDE4D | |
| SCHEMBL4147303 | 0.89 | PDE10A (0.72) | PDE10ALGALS3PDE4D | |
| SCHEMBL4154282 | 0.88 | PDE10A (0.55) | PDE10ALGALS3PDE4D | |
| SCHEMBL4147718 | 0.88 | PDE10A (0.54) | PDE10ALGALS3PDE4D | |
| SCHEMBL13036707 | 0.87 | PDE10A (0.65) | PDE10ALGALS3PDE4D | |
| SCHEMBL1423674 | 0.87 | PDE10A (0.71) | PDE10ALGALS3PDE4D | |
| SCHEMBL30123628 | 0.87 | PDE10A (0.56) | PDE10ALGALS3PDE4D | |
| SCHEMBL3272329 | 0.87 | PDE10A (0.56) | PDE10ALGALS3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117751107-A | Organic pyridine-pyrazole compounds and uses thereof | 博善人工智能剑桥有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023007184-A1 | ORGANIC PYRIDINE-PYRAZOLE COMPOUNDS AND THEIR USES | Benevolentai Cambridge Limited (GB) | 2023-02-02 | — | — | WO | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| CN-102491969-B | Heteroaromatic quinoline compounds and the purposes as PDE10 inhibitor thereof | PFIZER PRODUCTS INC. (US) | 2015-08-19 | — | — | CN | disclosed |
| CN-102491969-A | Heteroaromatic quinoline compounds | PFIZER PROD INC | 2012-06-13 | — | — | CN | disclosed |
| EP-2400991-A1 | RADIOLABELLED PDE10 LIGANDS | Janssen Pharmaceutica, N.V. (BE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110305637-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA N.V. | 2011-12-15 | — | — | US | disclosed |
| US-20110305637-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA N.V. | 2011-12-15 | — | — | US | disclosed |
| US-20110305637-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA N.V. | 2011-12-15 | — | — | US | disclosed |
| WO-2010097367-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097367-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-02 | — | — | WO | disclosed |
| EP-1841757-B1 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PROD INC (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7429665-B2 | Heteroaromatic quinoline compounds | PFIZER INC (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429665-B2 | Heteroaromatic quinoline compounds | PFIZER INC (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PFIZER INC | 2008-09-04 | — | — | US | disclosed |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PFIZER INC | 2008-09-04 | — | — | US | disclosed |
| EP-1841757-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Pfizer Products Incorporated (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PFIZER INC | 2006-07-13 | — | — | US | disclosed |
| WO-2006072828-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PDE12, PDE7A, PDE4A | PDE10A 8/4885LGALS3 4568/4885PDE4D 17/4885 |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PDE12, PDE7A, PDE4A | PDE10A 8/4885LGALS3 4568/4885PDE4D 17/4885 |
| US-20110305637-A1 | RADIOLABELLED PDE10 LIGANDS | PDE9A, PDE10A, PDE7A | PDE10A 2/4885LGALS3 2710/4885PDE4D 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.